Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (81-90 of 186) with videos related to

Pageof 19
Sort By:
BMC Cancer|June 8, 2021
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancerHiromichi Nakajima, Daisuke Kotani, Hideaki Bando, et al.
International Journal of Clinical Oncology|June 10, 2025
Physical activity and cancer biology: a narrative review of molecular mechanisms and introduction of the SCRUM-MONSTAR LIFELOG studyShugo Yajima, Shin Kobayashi, Tadayoshi Hashimoto, et al.
Anticancer Research|October 1, 2021
Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective AnalysisTaiko Nakazawa, Yukiya Narita, Ryosuke Kumanishi, et al.
Journal of Gastroenterology|May 31, 2024
Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinomaTakumi Habu, Shogo Kumagai, Hideaki Bando, et al.
Investigational New Drugs|May 21, 2021
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II studyDaisuke Kotani, Takayuki Yoshino, Masahito Kotaka, et al.
Esophagus : Official Journal of the Japan Esophageal Society|January 3, 2023
The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinomaYuki Matsubara, Kazuhiro Toriyama, Shigenori Kadowaki, et al.
Cancer Science|March 2, 2026
Single-Cell Analysis Identified a Recurrent Malignant-Associated Transcriptional State in Colorectal CancerSadahiro Iwabuchi, Kentaro Sawada, Motohiro Kojima, et al.
Medical Oncology (Northwood, London, England)|January 3, 2012
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|June 25, 2025
Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy for Very Low-Lying Clinical T3 Rectal Cancer: The NAIR Phase 2/3 Randomized Clinical TrialYuichiro Tsukada, Norio Saito, Yuji Nishizawa, et al.
Frontiers in Oncology|June 5, 2026
Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case reportNobuyuki Takahashi, Kenichi Harano, Chikako Funasaka, et al.
Pageof 19

Showing results (81-90 of 186) with videos related to

Sort By:
Pageof 19
BMC Cancer|June 8, 2021
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancerHiromichi Nakajima, Daisuke Kotani, Hideaki Bando, et al.
International Journal of Clinical Oncology|June 10, 2025
Physical activity and cancer biology: a narrative review of molecular mechanisms and introduction of the SCRUM-MONSTAR LIFELOG studyShugo Yajima, Shin Kobayashi, Tadayoshi Hashimoto, et al.
Anticancer Research|October 1, 2021
Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective AnalysisTaiko Nakazawa, Yukiya Narita, Ryosuke Kumanishi, et al.
Journal of Gastroenterology|May 31, 2024
Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinomaTakumi Habu, Shogo Kumagai, Hideaki Bando, et al.
Investigational New Drugs|May 21, 2021
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II studyDaisuke Kotani, Takayuki Yoshino, Masahito Kotaka, et al.
Esophagus : Official Journal of the Japan Esophageal Society|January 3, 2023
The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinomaYuki Matsubara, Kazuhiro Toriyama, Shigenori Kadowaki, et al.
Cancer Science|March 2, 2026
Single-Cell Analysis Identified a Recurrent Malignant-Associated Transcriptional State in Colorectal CancerSadahiro Iwabuchi, Kentaro Sawada, Motohiro Kojima, et al.
Medical Oncology (Northwood, London, England)|January 3, 2012
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|June 25, 2025
Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy for Very Low-Lying Clinical T3 Rectal Cancer: The NAIR Phase 2/3 Randomized Clinical TrialYuichiro Tsukada, Norio Saito, Yuji Nishizawa, et al.
Frontiers in Oncology|June 5, 2026
Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case reportNobuyuki Takahashi, Kenichi Harano, Chikako Funasaka, et al.
Pageof 19